Trump strikes new drug pricing deals with nine midsized drugmakers
President Donald Trump secured drug pricing agreements with nine pharmaceutical companies, including Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, and CSL. These pacts aim to align U.S. drug costs with international prices and require lower pricing for state Medicaid programs. This expansion brings the total number of participating companies to 26. While the administration targets lower costs for Americans, analysts do not expect the agreements to meaningfully impact the profits of the participating drugmakers.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Nine pharmaceutical companies signed new drug pricing agreements with the Trump administration.
- ✓ The new agreements focus on providing lower prices to state Medicaid programs.
- ✓ The total number of drugmakers under these pricing deals has reached 26.
What changed
The administration expanded the program to include nine mid-sized companies, raising the total count of participating drugmakers to 26.
Live updates
-
Trump adds nine drugmakers to Most Favored Nation pricing program
President Donald Trump secured drug pricing agreements with nine pharmaceutical companies, including Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, and CSL. These pacts aim to align U.S. drug costs with international prices and require lower pricing for state Medicaid programs. This expansion brings the total number of participating companies to 26. While the administration targets lower costs for Americans, analysts do not expect the agreements to meaningfully impact the profits of the participating drugmakers.
Why it matters
The administration previously reached similar deals with 17 of the largest pharmaceutical companies globally. This latest round shifts focus toward mid-cap biotechnology and pharmaceutical firms. The program utilizes a Most Favored Nation pricing model to reduce domestic healthcare spending.
What is confirmed
- Nine pharmaceutical companies signed new drug pricing agreements with the Trump administration.
- The new agreements focus on providing lower prices to state Medicaid programs.
- The total number of drugmakers under these pricing deals has reached 26.
Still unconfirmed
- The program aims to align U.S. drug prices with international prices.
What to watch next
- Implementation dates for the new Medicaid pricing tiers
- Financial reports from the nine mid-cap firms to verify profit impacts
- Further expansion of the program to additional biotech firms
confidence 90%Sources used for this update (4)
- www.pharmexec.com — Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing
- www.biopharmadive.com — Mid-cap biotechs join Trump’s latest round of drug pricing deals
- finance.yahoo.com — Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
- finance.yahoo.com — Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
-
Trump strikes drug pricing deals with nine midsize drugmakers
The Trump administration has announced new Medicaid drug pricing agreements with nine midsize biotechnology and pharmaceutical companies. These deals require the companies to provide lower prices to state Medicaid programs nationally. The agreements build on previous deals struck with 17 of the world's largest drugmakers. The move is part of Trump's efforts to lower drug prices for Americans.
Why it matters
The Trump administration has been focusing on reducing drug prices, a key concern for many Americans. The new agreements aim to provide lower prices for Medicaid programs, which could help millions of Americans who rely on these programs for their healthcare. The deals also reflect the administration's efforts to increase transparency and competition in the pharmaceutical industry. The impact of these agreements on the broader healthcare landscape remains to be seen.
What is confirmed
- The deals will require the companies to provide lower prices to state Medicaid programs nationally.
- The agreements build on previous deals struck with 17 of the world's largest drugmakers.
- Nine midsize biotechnology and pharmaceutical companies are involved in the new agreements.
What to watch next
- The impact of these agreements on drug prices for Americans
- Reactions from the pharmaceutical industry and lawmakers
- The potential expansion of these agreements to include more companies or programs
confidence 85%Sources used for this update (11)
- CNBC — Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
- Axios — Nine more drugmakers cut pricing deals with Trump
- Yahoo Finance — Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
- The New Republic — Trump, 80, Zonks Out as His Team Brags He’s Fixed Health Care
- thehill.com — Live updates: Donald Trump rolls out new lower drug prices; House returns from recess
- en.sedaily.com — Trump Presses Refiners, Fed as Gasoline Prices Surge Before Midterms
- www.nbcnews.com — Trump announces new drug-pricing deals with 9 pharma companies
- www.yahoo.com — Trump announces Medicaid drug pricing deals with 9 firms
- finance.yahoo.com — Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
- finance.yahoo.com — Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
- www.statnews.com — Trump strikes nine more deals with drugmakers to lower prices
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community